BridGene Biosciences

BridGene Biosciences specializes in drug discovery and development, utilizing its proprietary Chemoproteomics platform, IMTAC™. In October 2025, BridGene Biosciences, Inc. BridGene Biosciences primarily specializes in the discovery and development of innovative small molecules aimed at targeting high-value yet previously undruggable proteins associated with various diseases. The company's flagship offering is its proprietary Chemoproteomics platform, known as IMTAC™ (Isobaric Mass Tagged Affinity Characterization), which facilitates the screening of small molecules against the entire proteome of live cells. This technology enables the identification of drug candidates for challenging targets, such as oncogenic mutations, that are difficult to address with traditional therapies.BridGene Biosciences generates revenue through strategic partnerships and collaborations primarily with large pharmaceutical companies, such as Takeda. These partnerships often include upfront payments for access to BridGene's IMTAC™ technology, as well as milestone payments tied to the progression of specific drug discovery programs. For example, BridGene is eligible to receive substantial milestone payments as each collaboration achieves clinical and commercial milestones. The revenue model is structured around B2B transactions, where BridGene provides its proprietary technology and expertise in drug discovery to pharmaceutical partners, creating a stream of income through licensing agreements and potential royalties from future drug sales derived from these collaborations. The specific financial details of these arrangements are generally not disclosed publicly, reflecting the proprietary nature of the agreements.

1. Series B

   Oct 16, 2025

   Amount

   $28M

   Investors

   Locked

2. Series B

   Jul 27, 2022

   Amount

   $39M

   Investors

   Locked

3. Series A

   May 5, 2021

   Amount

   $12M

   Investors

   Locked